MoonLake Immunotherapeutics (MLTX) Stock Ticker
MLTX right now
Market factors today
Unlock the full MLTX picture
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
MLTX stock facts
| Ticker symbol | MLTX |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $1.0B |
| CEO | Jorge Santos da Silva |
| Employees | 130 |
| Headquarters | Zug, ZG, CH |
| IPO date | 2020-10-20 |
| Website | www.moonlaketx.com |
What you can see for MLTX on Tickr
Live MLTX price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the MLTX report.
Rankings
FAQ
What is the ticker symbol for MoonLake Immunotherapeutics?
The ticker symbol for MoonLake Immunotherapeutics is MLTX, listed on the NASDAQ Capital Market.
What is MLTX?
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials…